Literature DB >> 8315946

Alpha 1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis.

V L Esnault1, A Testa, M Audrain, C Rogé, M Hamidou, J H Barrier, R Sesboüé, J P Martin, P Lesavre.   

Abstract

Alpha 1-antitrypsin (alpha 1-AT) is the major inhibitor of proteinase 3 (PR3), the main target antigen of antineutrophil cytoplasm antibodies (ANCA) in Wegener's granulomatosis. alpha 1-AT is encoded by a polymorphic gene, with over 75 alleles, defining severely, medium and non-deficient protease inhibitor (PI) phenotypes. We describe the association of severely and medium deficient PI phenotypes with anti-PR3 positive systemic vasculitis, and postulate a pathogenetic role for alpha 1-AT deficiency and the occurrence of ANCA, with specificity for PR3 in a subgroup of patients with Wegener's granulomatosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8315946     DOI: 10.1038/ki.1993.186

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  45 in total

1.  Immunogenetic risk factors for anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis.

Authors:  M Gencik; S Borgmann; R Zahn; E Albert; T Sitter; J T Epplen; H Fricke
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

Review 2.  Pathogenesis and treatment of ANCA-associated systemic vasculitis.

Authors:  A D Salama
Journal:  J R Soc Med       Date:  1999-09       Impact factor: 5.344

Review 3.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

4.  Increased neutrophil membrane expression and plasma level of proteinase 3 in systemic vasculitis are not a consequence of the - 564 A/G promotor polymorphism.

Authors:  M Abdgawad; T Hellmark; L Gunnarsson; K W A Westman; M Segelmark
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

Review 5.  Pulmonary vasculitis.

Authors:  A Burns
Journal:  Thorax       Date:  1998-03       Impact factor: 9.139

6.  [The genetics of vasculitides].

Authors:  J U Holle; S Wieczorek; J T Epplen; W L Gross
Journal:  Z Rheumatol       Date:  2011-04       Impact factor: 1.372

Review 7.  ANCA-associated diseases and silica exposure.

Authors:  G Gregorini; P Tira; J Frizza; P C D'Haese; M M Elseviers; G Nuyts; R Maiorca; M E De Broe
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 8.667

8.  Genetically determined severity of anti-myeloperoxidase glomerulonephritis.

Authors:  Hong Xiao; Dominic Ciavatta; David L Aylor; Peiqi Hu; Fernando Pardo-Manuel de Villena; Ronald J Falk; J Charles Jennette
Journal:  Am J Pathol       Date:  2013-02-04       Impact factor: 4.307

Review 9.  Neutrophil proteinase 3 and dipeptidyl peptidase I (cathepsin C) as pharmacological targets in granulomatosis with polyangiitis (Wegener granulomatosis).

Authors:  Brice Korkmaz; Adam Lesner; Stephanie Letast; Yassir K Mahdi; Marie-Lise Jourdan; Sandrine Dallet-Choisy; Sylvain Marchand-Adam; Christine Kellenberger; Marie-Claude Viaud-Massuard; Dieter E Jenne; Francis Gauthier
Journal:  Semin Immunopathol       Date:  2013-02-06       Impact factor: 9.623

10.  [Genetic risk factors for vasculitis].

Authors:  J U Holle; W L Gross
Journal:  Internist (Berl)       Date:  2014-02       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.